Tuberculosis and Respiratory Diseases

  • 제87권3호
  • /
  • Pages.292-301
  • /
  • 2024
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Contemporary Strategies: Incorporating Immunotherapy into Stage 3 Non-small Cell Lung Cancer Treatment

  • Da Hyun Kang (Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University) ;
  • Chaeuk Chung (Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University)
  • 투고 : 2023.10.08
  • 심사 : 2024.03.22
  • 발행 : 2024.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Stage 3 non-small cell lung cancer (NSCLC) exhibits significant diversity, making it challenging to define an optimal treatment. A collaborative multidisciplinary approach is essential in crafting individualized treatments. Previously, targeted therapies and immunotherapies were commonly used to treat patients with advanced and metastatic lung cancer. Such treatments are now being extended to individuals considered surgery, as well as patients once considered unsuitable for surgery. These changes have increased surgical success and substantially reduced postoperative recurrence. However, the possibility of severe adverse effects from immunotherapy can deter some patients from performing surgery. It is essential to carefully explore the clinical traits and biomarkers of patients who may benefit the most from immunotherapy, and patients for whom immunotherapy should not be prescribed. In summary, it's crucial to effectively integrate the latest immunotherapy in treating stage 3 NSCLC patients, thereby increasing their opportunities for surgical intervention, and ensuring they receive the best possible care.

키워드

과제정보

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (No. NRF2022R1A2C2010148) and grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR20C0025).

참고문헌

  1. Dickhoff C, Heineman DJ, Bahce I, Senan S. Unresectable stage III NSCLC can be reevaluated for resectability after initial treatment. J Thorac Oncol 2023;18:1124-8. https://doi.org/10.1016/j.jtho.2023.06.002
  2. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008;86:912-20. https://doi.org/10.1016/j.athoracsur.2008.04.073
  3. Majem M, Hernandez-Hernandez J, Hernando-Trancho F, Rodriguez de Dios N, Sotoca A, Trujillo-Reyes JC, et al. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clin Transl Oncol 2020;22:21-36. https://doi.org/10.1007/s12094-019-02134-7
  4. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020;383:1711-23. https://doi.org/10.1056/NEJMoa2027071
  5. Hoeijmakers F, Heineman DJ, Daniels JM, Beck N, Tollenaar RA, Wouters MW, et al. Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer. Chest 2020;158:2675-87. https://doi.org/10.1016/j.chest.2020.07.054
  6. Rizvi NA, Peters S. Immunotherapy for unresectable stage III non-small-cell lung cancer. N Engl J Med 2017;377:1986-8. https://doi.org/10.1056/NEJMe1711430
  7. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976-86. https://doi.org/10.1056/NEJMoa1716078
  8. Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Casal-Rubio J, Domine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020;21:1413-22. https://doi.org/10.1016/S1470-2045(20)30453-8
  9. Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020;21:786-95. https://doi.org/10.1016/S1470-2045(20)30140-6
  10. Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398:1344-57. https://doi.org/10.1016/S0140-6736(21)02098-5
  11. Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med 2022;28:2155-61. https://doi.org/10.1038/s41591-022-01962-5
  12. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386:1973-85. https://doi.org/10.1056/NEJMoa2202170
  13. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):iv1-21. https://doi.org/10.1093/annonc/mdx222
  14. Unal S, Winkelman JA, Heineman DJ, Bahce I, van Dorp M, Braun JA, et al. Long-term outcomes after chemoradiotherapy and surgery for superior sulcus tumors. JTO Clin Res Rep 2023;4:100475.
  15. Lee VH, Au JS, Mu JW, Xiao G, Lim FM, Suen HC, et al. Real-world perspectives from surgeons and oncologists on resectability definition and multidisciplinary team discussion of stage III NSCLC in People's Republic of China, Hong Kong, and Macau: a physician survey. JTO Clin Res Rep 2022;3:100308.
  16. Scherpereel A, Martin E, Brouchet L, Corre R, Duruisseaux M, Falcoz PE, et al. Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer. Lung Cancer 2023;177:21-8. https://doi.org/10.1016/j.lungcan.2023.01.008
  17. Vyfhuis MA, Bhooshan N, Burrows WM, Turner M, Suntharalingam M, Donahue J, et al. Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. Adv Radiat Oncol 2017;2:259-69. https://doi.org/10.1016/j.adro.2017.07.009
  18. Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, et al. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. J Thorac Cardiovasc Surg 2022;164:1587-602. https://doi.org/10.1016/j.jtcvs.2022.03.034
  19. Liu KX, Sierra-Davidson K, Tyan K, Orlina LT, Marcoux JP, Kann BH, et al. Surgical complications and clinical outcomes after dose-escalated trimodality therapy for nonsmall cell lung cancer in the era of intensity-modulated radiotherapy. Radiother Oncol 2021;165:44-51. https://doi.org/10.1016/j.radonc.2021.10.012
  20. Lee JG, Kim HC, Choi CM. Recent trends of lung cancer in Korea. Tuberc Respir Dis (Seoul) 2021;84:89-95. https://doi.org/10.4046/trd.2020.0134
  21. Simone CB 2nd, Bradley J, Chen AB, Daly ME, Louie AV, Robinson CG, et al. ASTRO radiation therapy summary of the ASCO guideline on management of stage III nonsmall cell lung cancer. Pract Radiat Oncol 2023;13:195-202. https://doi.org/10.1016/j.prro.2023.01.005
  22. Heymach JV, Mitsudomi T, Harpole D, Aperghis M, Jones S, Mann H, et al. Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: the AEGEAN Trial. Clin Lung Cancer 2022;23:e247-51. https://doi.org/10.1016/j.cllc.2021.09.010
  23. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919-29. https://doi.org/10.1056/NEJMoa1709937
  24. Provencio M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, Bernabe R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non-smallcell lung cancer. N Engl J Med 2023;389:504-13. https://doi.org/10.1056/NEJMoa2215530
  25. O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA nonsmall-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23:1274-86. https://doi.org/10.1016/S1470-2045(22)00518-6
  26. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage nonsmall-cell lung cancer. N Engl J Med 2023;389:491-503. https://doi.org/10.1056/NEJMoa2302983
  27. Dickhoff C, Otten RH, Heymans MW, Dahele M. Salvage surgery for recurrent or persistent tumour after radical (chemo)radiotherapy for locally advanced non-small cell lung cancer: a systematic review. Ther Adv Med Oncol 2018;10:1758835918804150.
  28. Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 2021;27:504-14. https://doi.org/10.1038/s41591-020-01224-2
  29. Petrella F, Rizzo S, Attili I, Passaro A, Zilli T, Martucci F, et al. Stage III non-small-cell lung cancer: an overview of treatment options. Curr Oncol 2023;30:3160-75. https://doi.org/10.3390/curroncol30030239
  30. Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol 2022;40:3383-93.  https://doi.org/10.1200/JCO.22.00227